BioTrove designs, manufactures and sells devices that aid in biomedical research and new drug development. more...

LumeRx, Inc. has developed, patented, and is currently building its clinical instrument for an endoscopically delivered treatment to eradicate H.pylori in the stomach without antibiotics, thereby curing peptic ulcer disease, in a single outpatient procedure. more...

[X+1], (formerly Poindexter Systems), is a marketing technology and solutions company that improves the profitability of a marketer’s online programs. more...

Avedro, Inc. has created and patented a device to correct vision by reshaping the cornea without incision. more...

SiteScape, Inc.'s Forum application is a leader in the Internet based Team Collaboration Application market. more...

BioTrove designs, manufactures and sells devices that aid in biomedical research and new drug development. BioTrove, whose technology has origins in MIT's BioInstrumentation Lab, has two complementary product lines, the Living Chip, a patented platform for genomic research and drug development, and Momentum, a system for label-free small molecule drug discovery. The Living Chip is a genomic experiment platform that decreases the cost of PCR ("Polymerase Chain Reaction") by orders of magnitude by increasing the number of PCR experiments that researchers can do. With the Living Chip, researchers can, on a standard 3"X 5"-sized format, go from 96 to 24,000 simultaneous PCR experiments. This allows researchers to reach experimental end-points 5 to 25X faster, at a lower cost, and with significantly better results. The Living Chip is truly an enabling technology. By reducing the cost of PCR so dramatically it becomes feasible to use PCR in a much wider range of genomic experiments. Momentum combines chromatography and mass spectrometry to make label-free, high-throughput screening of certain types of "target" molecules (those that researchers believe play a role in a disease), such as lipids and fatty acids, that are considered "intractable" because they are hard to screen against inorganic compounds that might affect them and through them, the disease. Echelon Advisor, Illona Rimm, assisted us in evaluating the technology, the markets and the prospects for a profitable exit. Co-investors include Pfizer, CB Health Ventures, Zero Stage Capital, Catalyst health & Technology Partners and BioFrontier Ventures.

Back to the top

LumeRx, Inc. Peptic ulcer disease is not caused by stress. The causative agent is a bacterium called H. pylori, which is also strongly associated with gastric stomach cancer. Epidemiologists estimate that one-half of the world’s population, and up to 100% of some Asian populations, have an H. pylori infection in the stomach. LumeRx has developed, patented, and is currently building its clinical instrument for an endoscopically delivered treatment to eradicate H.pylori in the stomach without antibiotics, thereby curing peptic ulcer disease, in a single outpatient procedure. Dr. Tony Lembo advises Echelon Ventures on LumeRx.

Back to the top

[X+1], (formerly Poindexter Systems), is a marketing technology and solutions company that improves the profitability of a marketer’s online programs. Since 1999, the Company has pioneered the emerging class of Marketing Optimization with its proven innovative technology and insightful partnership. [X+1] performance solutions have typically augmented its client’s conversion efficiency by over 100% over time. Investors include Echelon Ventures, Hudson Partners, Blue Chip Ventures and Waller Sutton Capital.

Back to the top

Avedro, Inc. has created and patented a device to correct vision by reshaping the cornea without incision. The device uses microwave energy for about one second in a safe treatment that can be delivered in less than three minutes at far less cost than LASIK. The Company's Microwave Thermal Keroplasty ("MTK") technology has been developed over several years at Dartmouth's Thayer School of Engineering and the Dartmouth Medical Center. The device includes a standard microwave generator and an applicator with which the surgeon applies a ring of microwave energy around the pupil, outside the field of vision. The technology is licensed exclusively from Dartmouth College, and is subject to one issued and two patent applications covering the use of microwaves for reshaping the cornea, as well as the methodology for application. Echelon Advisor, Stu Randle, assisted us in evaluating the technology, the markets and the prospects for a successful exit. Stu has over 20 years of operating experience in medical devices and healthcare products ranging from sales engineering to CEO. Recently, he was CEO of Optobionics, a company that is developing an artificial retina and related devices to restore vision for individuals afflicted with retinal diseases that can lead to blindness.

Back to the top

SiteScape, Inc.'s Forum application is a leader in the Internet based Team Collaboration Application market. By using Forum to collaborate on their workflow over the Internet, SiteScape's customers realize major savings in time and money. Shell Oil, for one, asserts that SiteScape Forum saves their company $200 million per year in hard, measurable costs. Originally developed by DEC, SiteScape acquired Forum from Compaq in 1999 when Compaq bought DEC. Since then, SiteScape has added 300 enterprise customers. Customers include, for example, Shell Oil, Halliburton, Lockheed Martin, Lehman Brothers, Davis Polk Wardwell, and Rio Tinto. SiteScape sells directly and through strategic partners, including SAIC, a $6.5 billion systems integrator. Echelon invested together with SAIC Venture Capital Corp., the venture capital subsidiary of SAIC picked SiteScape Forum as the best of the TCA applications and chose SiteScape as its preferred vendor for its corporate information portal project. SiteScape is headquartered in Maynard, Mass. with offices in Alexandria, Va, Wilmington, NC and the Netherlands. Ron Bohlin, an advisor to Echelon Ventures represents Echelon Ventures on the Board.

Back to the top